Expression of miR-652-3p and Effect on Apoptosis and Drug Sensitivity in Pediatric Acute Lymphoblastic Leukemia

Table 3

Clinical characteristics of the three pediatric patients with ALL¹ who relapsed (BM samples).

	Case 1	Case 2	Case 3
Sex	Male	Male	Male
Age (at ND)	4.3	5.11	8.4
WBC number (at ND)	69.67	127	27.75
Blast cells in CSF (at ND)	Negative	Negative	Negative
Percentage of blast cells in BM puncture (at ND)	97%	92%	95%
Immunophenotyping	Common B cell	Common B cell	Common B cell
Fusion gene	TEL-AML1	TEL-AML1	None
Risk stratification	Intermediate-risk	Intermediate-risk	Intermediate-risk
CNS involvement	Yes	No	No
Prednisone response on Day 8	Favorable	Favorable	Favorable
BM response on Day 15 by morphology	CR	PR	CR
BM response on Day 33 by morphology	CR	CR	CR
CR duration (months)	41	53	26

ALL: acute lymphoblastic leukemia; BM: bone marrow; CR: complete remission; CNS: central nervous system; CSF, cerebrospinal fluid; WBC: white blood cell; ND: new diagnosis; PR: partial remission.
The patients were classified as standard-risk, intermediate-risk, and high-risk groups according to age, WBC count, immunophenotype, cytogenetic and molecular aberrations, prednisone response, morphological remission at the end of induction therapy (based on BFM risk criteria), and minimal residual disease (MRD) at the end of induction therapy and the beginning of consolidation therapy [24–27].
¹These three patients were from the 86 patients whose details are summarized in Table 2.